Form 4: ResMed CPO Leong Acquires 5,462 Shares

ResMed's Chief Product Officer, Justin Leong, acquired 5,462 shares of common stock through the vesting of performance-based restricted stock units.

Summary

• Justin Leong, Chief Product Officer of ResMed Inc. (RMD), acquired 5,462 shares of ResMed Common Stock.
• The acquisition occurred on August 15, 2025, and was reported on August 19, 2025.
• These shares were earned from performance-based restricted stock units (RSUs) that were granted on November 20, 2024.
• The compensation committee certified that the performance metrics for these RSUs were met, leading to the earning of these shares.
• Following this transaction, Leong beneficially owns a total of 27,180 shares of ResMed Common Stock.
• The stock units vest 1/3 each year on the anniversary of the grant date.

Sentiment

Score: 7

Explanation: The filing reports a routine executive stock acquisition due to performance-based RSU vesting, indicating that performance metrics were met. This is generally positive as it aligns executive interests with shareholders and suggests good company performance, but it's a standard compensation event rather than a new strategic announcement.

Positives

• The acquisition of shares by a key executive (Chief Product Officer) increases their direct ownership, aligning their interests with those of shareholders.
• The shares were earned because performance metrics were met, which suggests positive company performance leading up to the earning date.

Future Outlook

The filing indicates that performance metrics for the granted restricted stock units were met, suggesting positive past performance leading up to the earning date. The vesting schedule of 1/3 each year on the anniversary of the grant implies continued long-term incentive alignment for the executive.

Management Comments

• Represents performance-based restricted stock units granted on November 20, 2024.
• The shares were earned on August 15, 2025, when the compensation committee certified that the performance metrics were met.
• Stock units vest 1/3 each year on the anniversary of the grant.

Industry Context

This Form 4 filing is a routine disclosure of executive compensation and insider ownership changes. It reflects standard practices in the medical device and healthcare technology industry where performance-based equity awards are common to align executive incentives with company performance and shareholder value.

Comparison to Industry Standards

• The use of performance-based restricted stock units (RSUs) is a common compensation practice across publicly traded companies, including those in the medical device sector such as Medtronic, Philips, and Stryker.
• The vesting schedule of 1/3 annually is standard for long-term incentive plans, promoting executive retention and sustained performance.
• The acquisition of shares at a $0 price is typical for RSU vesting, as it represents the conversion of an equity award into common stock rather than a cash purchase.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value due to increased executive ownership.
• Employees: May signal positive company performance, potentially boosting morale.

Next Steps

• Continued vesting of the remaining performance-based restricted stock units on the anniversary of the November 20, 2024 grant date.

Key Dates

Recommendation

This Form 4 reports a routine executive stock acquisition through the vesting of performance-based restricted stock units, indicating that performance metrics were met. While positive for executive alignment and reflecting past performance, it does not provide new fundamental information to warrant a change in investment recommendation. It's a standard compensation event rather than a strategic or financial announcement that would significantly alter the company's outlook.

Keywords

ResMed, RMD, Insider Trading, Form 4, Stock Acquisition, Restricted Stock Units, Executive Compensation, Justin Leong, Chief Product Officer